Category: Company Updates

This category can only be viewed by members. To view this category, sign up by purchasing One Year Individual Subscription, One Year Individual Subscription (Digital), Two Year Individual Subscription, Two Year Individual Subscription (Digital), Three Year Individual Subscription, Three Year Individual Subscription (Digital), One Year Group Subscription, One Year Group Subscription (Digital), Two Year Group Subscription, Two Year Group Subscription (Digital), Three Year Group Subscription or Three Year Group Subscription (Digital).

Novavax Update (1-25-13)

NVAX has cleared an important hurdle tied to the government funding for their seasonal and pandemic flu vaccine program.  The U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review of the company’s contract.   Subsequently, BARDA has notified NVAX that a milestone decision has been made to[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Anthera Update (1-18-13)

Anthera has switched gears as they recently disclosed that development program testing blisibimod in lupus is on hold as the company searches for a partner that will fund further development. This is a disappointment as ANTH had previously planned to start Phase III development for lupus this year.  ANTH now says that that they are[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Incyte Update (1-18-13)

Incyte’s stock has had a nice move to start the year. The company presented at JP Morgan and did a good job of detailing how they will grow Jakafi sales.  Importantly, some on Wall Street also believe that INCY has learned a lot from the launch over the last year and are positioned to grow[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

ImmunoGen Update (1-18-13)

With T-DM1 FDA approval nearing the goal line – the PDUFA date is February 26 – ImmunoGen will join the ranks of commercially successful biotech companies, a major achievement. While it is widely known that the royalty rate IMGN will receive from partner Roche (~3%) is unlikely to lead the company to major profitability, regulatory[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Anthera Update (1-19-13)

Anthera announced last week that they priced a public offering of 60 million shares at $0.66 per share, which will add $40 million to their balance sheet.  Jefferies is acting as sole book-running manager in the offering and Leerink Swann is acting as co-manager.  These are quality investment banks and it is an impressive accomplishment for[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Pacira Update (1-18-13)

On a positive note, Pacira pre-released some of their key Q4 financials. The company expects Q4:12 and FY12 revenues to come in above Wall Street consensus estimates, driven by higher net sales of Exparel.  Q4 sales of the drug are targeted at $7.8 million, and total revenues are estimated at $10.5 million, compared to $4.2[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Sangamo Update (1-18-13)

Sangamo’s stock has risen sharply (~35%) since their presentation last week at the JP Morgan conference. The company broadly explained what their novel technology – In Vivo Protein Replacement – has the ability to accomplish.  It has the ability to mechanistically, physically, and permanently change a single disease related gene (“monogenic”) and, therefore, has substantial[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Alkermes Update (1-18-13)

OUTLOOK 2013 – RAISING BUY LIMIT AND TARGET PRICE Over the past decade, Alkermes has evolved into a fully integrated company as they receive revenue from five ALKS-developed approved drugs and have established a real R&D pipeline. ALKS has emerged as a leader in the development of injectable antipsychotics that can be administered as infrequently[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Pharmacyclics Update (1-18-13)

We attended the Pharmacyclics‘ presentation and breakout session at JP Morgan. While the company repeated much of the powerful ASH data from a month earlier, we did learn some new and not unimportant pieces of information.  First, the company is about to open RESONATE 17 – a likely fast-track registration trial of ibrutinib (the fourth[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (1-18-13)

Isis’ stock has been strong, pre- and post-JP Morgan. Wall Street is beginning to warm up to the story, as we believe; the deep pipeline from late-stage to early-stage compounds is attracting more investors.  The recent partnerships with Biogen and AstraZeneca for certain early-stage drug development candidates have convinced some that antisense has real potential. The[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Celgene Update (1-18-13)

OUTLOOK 2013, RAISING BUY LIMIT AND TARGET PRICE As recently as the summer of 2012, Celgene had a stable but slowing core business led by Revlimid but no apparent pipeline.  Questions arose about the company’s long-term growth. In a remarkable turn of events, the company and stock have been revived by not one but three[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Coronado Update (1-18-13)

Our #1 pick for 2013 We met with Coronado Biosciences’ new CEO Harlan Weisman during JP Morgan. We have known Dr. Weisman since our days as a Centocor analyst in the 1990s where he was Chief Medical Officer and subsequently became Senior management at Johnson & Johnson (JNJ) after its acquisition of CNTO.  With his[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by